🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

42 results for “LIGAND” Clear

  1. [11C]CPPC PET ligand

    United Therapeutics Europe Ltd

    ALS

    phase 2 small molecule active

    1 trial

  2. bexarotene

    LIGAND PHARMACEUTICALS INC

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  3. bexarotene

    LIGAND PHARMACEUTICALS INC

    Cutaneous T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  4. denileukin diftitox

    LIGAND PHARMACEUTICALS INC

    Drug/Agent Toxicity by Tissue/Organ

    phase 2 mab completed

    1 trial

  5. erlotinib and bexarotene

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule completed

    1 trial

  6. irbesartan

    LIGAND PHARMACEUTICALS INC

    Hypertension

    phase 2 small molecule completed

    1 trial

  7. A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer

    Philogen S.p.A.

    Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

    phase 1 other active

    1 trial

  8. A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer.

    Philogen S.p.A.

    Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

    phase 1 other active

    1 trial

  9. Bexarotene (Targretin®)

    LIGAND PHARMACEUTICALS INC

    Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)

    phase 1 small molecule completed

    1 trial

  10. Imaging procedure to measure the distribution of a newly developed radiolabeled ligand for the oxytocin receptor

    Tonix Pharmaceuticals Holding

    Pain, Face

    phase 1 small molecule completed

    1 trial

  11. LGD-6972

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    2 trials

  12. LGD-6972 Solution

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus (T2DM)

    phase 1 small molecule completed

    1 trial

  13. NCO-48 Fumarate

    LIGAND PHARMACEUTICALS INC

    Hepatitis B

    phase 1 small molecule completed

    1 trial

  14. NCO-48 Fumarate 4 mg

    LIGAND PHARMACEUTICALS INC

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  15. Ramipril tablet 10 mg

    LIGAND PHARMACEUTICALS INC

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  16. Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg

    LIGAND PHARMACEUTICALS INC

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  17. ONTAK (denileukin difitox, DAB389IL-2)

    LIGAND PHARMACEUTICALS INC

    Lymphoma, T-Cell, Cutaneous

    approved small molecule completed

    1 trial

  18. erlotinib (Tarceva) and bexarotene (Targretin)

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources